<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00310531</url>
  </required_header>
  <id_info>
    <org_study_id>91213</org_study_id>
    <secondary_id>306871</secondary_id>
    <nct_id>NCT00310531</nct_id>
  </id_info>
  <brief_title>3-year Study of Menostar Versus Evista to Prevent Osteoporosis in Post-menopausal Women</brief_title>
  <official_title>A Multicenter, Double-Blind, Double-Dummy, Randomized, Active- Controlled, 3-Year Study to Evaluate the Antiresorptive Efficacy, Safety and Tolerability of a Ultra-Low Dose Estradiol Transdermal Delivery System Releasing 0.014 mg / Day Versus Oral Raloxifene Hydrochloride 60 mg / Day - as a Therapy for the Prevention of Osteoporosis in Postmenopausal Female Osteopenic Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this trial is to investigate whether the Menostar patch is as safe and effective
      in the prevention of bone loss in postmenopausal women as raloxifen, a drug already
      registered for prevention and treatment of osteoporosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been
      renamed to Bayer Schering Pharma AG, Germany.Bayer Schering Pharma AG, Germany is the sponsor
      of the trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2004</start_date>
  <completion_date type="Actual">June 2007</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage change in Bone Mineral Density at the lumbar spine</measure>
    <time_frame>after 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage change in Bone Mineral Density of the hip</measure>
    <time_frame>after 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change in biochemical markers of bone turnover</measure>
    <time_frame>after 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with hot flushes</measure>
    <time_frame>after 3 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Women's Health Questionnaire</measure>
    <time_frame>after 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with an abnormal endometrial biopsy</measure>
    <time_frame>after 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacogenetic analysis</measure>
    <time_frame>after 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Digital breast density analysis</measure>
    <time_frame>after 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">500</enrollment>
  <condition>Osteopenia</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Menostar (Estradiol, BAY86-5435)</intervention_name>
    <description>Menostar (estradiol transdermal delivery system (SHP00577E), 0.014 mg/day)</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raloxifene</intervention_name>
    <description>Raloxifene tbl. (60 mg/day)</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Last (regular) menstrual period more than 5 years ago

          -  Relative good state of health

          -  Intact, normal uterus

        Exclusion Criteria:

          -  Bone and musculoskeletal diseases

          -  Clinically significant vertebral fracture within the last 12 months

          -  Pre-existing cardiovascular disease (e.g. uncontrolled high/low blood pressure,
             stroke, thromboembolic event etc)

          -  Uncontrolled diabetes mellitus (or treated with insulin)

          -  Uncontrolled thyroid disorders

          -  Relevant renal disorder or significant liver dysfunction (including cholestasis)

          -  History of alcohol or drug abuse

          -  History of immobilization of more than 2 months in the last 6 months

          -  Smoking of more than 10 cigarettes per day

          -  Unexplained uterine bleeding

          -  Known or suspected malignant or premalignant disease (e.g. cancer of breast or uterus,
             melanoma)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://www.bayerpharma.com/en/research-and-development/clinical-trials/trial-finder/index.php</url>
    <description>Click here to find results for studies related to Bayer Healthcare products.</description>
  </link>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2006</study_first_submitted>
  <study_first_submitted_qc>March 31, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2006</study_first_posted>
  <last_update_submitted>December 29, 2014</last_update_submitted>
  <last_update_submitted_qc>December 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Raloxifene Hydrochloride</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

